Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 2031-2034

  Billecke, Lisa ^a   Penas, Eva Maria Murga ^a   May, Annette M ^b   Engelhardt, Monika ^b   Nagler, Arnon ^c   Leiba, Merav ^c   Schiby, Ginette ^c   Kröger, Nicolaus ^a   Zustin, Jozef ^a   Marx, Andreas ^a   Matschke, Jakob ^a   Tiemann, Markus ^d   Goekkurt, Eray ^e   Bokemeyer, Carsten ^a   Schilling, Georgia ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c SHEBA MEDICAL CENTER   (Israel)

^d Institute of Hematopathology   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

cIg FISH; Cytogenetics; Del (17)(p13); Extramedullary myeloma; Fluorescence in situ hybridization; Multiple myeloma; TP53

Indexed keywords

IMMUNOGLOBULIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BONE LESION; BONE MARROW; CANCER INFILTRATION; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN FUNCTION; SOFT TISSUE DISEASE; STAINING;

AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOLYSIS; SOFT TISSUE NEOPLASMS;

EID: 84861496164     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Minnema MC, van de Donk NW, Zweegman S, Hegenbart U, Schonland S, Raymakers R, Zijlmans JMJM, Kersten MJ, Bos GMJ and Lokhorst HM: Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant 41: 779-784, 2008. (Pubitemid 351696341)
2. Perez-Simon JA, Sureda A, Fernandez-Aviles F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás JF, Moraleda JM, Alegre A, Cañizo C, Brunet S, Rosiñol L, Lahuerta J, Díez- Martín JL, León A, García A, Vazquez L, Sierra J and San Miguel JF: Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 20: 542-545, 2006. (Pubitemid 43291766)
3. Zeiser R, Deschler B, Bertz H, Finke J and Engelhardt M: Extramedullary vs. medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 34: 1057-1654, 2004.
4. Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B and Arnold W: Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85: 2305- 2314, 1999.
5. López-Anglada L, Gutiérrez NC, García JL, Mateos MV, Flores T and San Miguel JF: p53 may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol 84: 359-361, 2010.
6. Chang H, Sloan S, Li D and Keith Stewart A: Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 127: 280-284, 2004. (Pubitemid 39468940)
7. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM and Greipp PR: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 21-33, 2003. (Pubitemid 36033957)
8. Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D and Marx A: Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol 89: 175-181, 2010.
9. Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, Perez-Simon JA, San Miguel JF, Kiehl M, Fauser A, Schwerdtfeger R, Wandt H, Sayer HG, Myint H, Klingemann H, Zabelina T, Dierlamm J, Hinke A and Zander AR: Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 103: 4056-4061, 2004. (Pubitemid 38685344)
10. Schilling G, Dierlamm J and Hossfeld DK: Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance. Hematol Oncol 23: 102-107, 2005. (Pubitemid 43061887)
11. Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D and Apperley JF: Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 75: 376-383, 2005. (Pubitemid 41445076)
12. Bink K, Haralambieva E, Kremer M, Ott G, Beham-Schmid C, de Leval L, Cheng Peh S, Laeng HR, Jütting U, Hutzler P, Quintanilla- Martinez L and Fend F: Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica 93: 623-626, 2008. (Pubitemid 351536395)
13. Schilling G, Hansen T, Shimoni A, Zabelina T, Simon-Perez JA, Gutierrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EMM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, Miguel JS, Nagler A and Kröger N: Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 22: 1250-1255, 2008. (Pubitemid 351833794)
14. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E and Terpos E: Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24: 1769-1778, 2010.
15. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ and Greipp PR: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101: 4569-4575, 2003. (Pubitemid 36857829)